Baltch A L, Hammer M, Smith R P, Sutphen N
J Lab Clin Med. 1979 Aug;94(2):201-14.
The susceptibility of 100 blood culture isolates of Pseudomonas aeruginosa observed during 4 1/2 years was tested for tobramycin, netilimicin, gentamicin, amikacin, pirbenicillin, ticarcillin and carbenicillin, singly and in combination. For aminoglycosides, the agar MICs were twofold to threefold greater than tube dilution MICs but for the penicillins they were similar. For aminoglycosides and ticarcillin, the MBCs were twofold greater than the tube dilution MICs. The MBCs were not achieved at concentrations as high as 512 micrograms/ml for 40% of the isolates for pirbenicillin and for 10% for carbenicillin. Tobramycin and pirbenicillin had the lowest MICs for the aminoglycosides and penicillins, respectively. Synergism was tested and observed between tobramycin + ticarcillin and amikacin + ticarcillin. No overall increase in resistance to gentamicin or carbenicillin was seen from 1974 to 1977. However, patients given repeated courses of gentamicin had more resistant strains. Following the administration of 1.5 mg/kg/dose of gentamicin, peak serum concentrations failed to achieve the MIC for the microorganism in 22% of the patients. The MIC was achieved in all patients receiving the same dose of tobramycin. The overall fatality rate was 67% with one third of the patients dying within 36 hr. There was no relationship of patient fatality rate and MIC for the microorganism. Although in the rapidly fatal group of all patients receiving inappropriate therapy died, the fatality rates of appropriately or inappropriately treated patients in the ultimately fatal and nonfatal groups were similar. Underlying host disease was the major determining factor in patient survival.
在4年半的时间里观察了100株铜绿假单胞菌血培养分离株对妥布霉素、奈替米星、庆大霉素、阿米卡星、哌拉西林、替卡西林和羧苄西林的敏感性,包括单独用药和联合用药。对于氨基糖苷类药物,琼脂稀释法测得的最低抑菌浓度(MIC)比试管稀释法高2至3倍,但对于青霉素类药物,二者相似。对于氨基糖苷类药物和替卡西林,最低杀菌浓度(MBC)比试管稀释法测得的MIC高2倍。对于40%的哌拉西林分离株和10%的羧苄西林分离株,在浓度高达512微克/毫升时仍未达到MBC。妥布霉素和哌拉西林分别对氨基糖苷类药物和青霉素类药物具有最低的MIC。测试并观察到妥布霉素+替卡西林以及阿米卡星+替卡西林之间存在协同作用。1974年至1977年期间,未观察到对庆大霉素或羧苄西林的总体耐药性增加。然而,接受重复疗程庆大霉素治疗的患者中有更多耐药菌株。给予1.5毫克/千克剂量的庆大霉素后,22%的患者血清峰值浓度未能达到微生物的MIC。所有接受相同剂量妥布霉素的患者均达到了MIC。总体死亡率为67%,三分之一的患者在36小时内死亡。患者死亡率与微生物的MIC之间没有关系。尽管在所有接受不适当治疗的患者的快速死亡组中患者均死亡,但在最终死亡组和非死亡组中,接受适当或不适当治疗的患者的死亡率相似。基础宿主疾病是患者生存的主要决定因素。